1. Introduction: The “Renaissance” of Wound Antisepsis
As clinicians, we are currently witnessing a “renaissance” in wound antisepsis. For decades, the convenience of systemic antibiotics overshadowed the use of topical antiseptics; however, the tide has turned. This resurgence is driven by three critical clinical realities: the global pandemic of multidrug-resistant organisms (MDROs), the high rate of patient sensitization to local antibiotics, and the fact that non-specific antiseptics—which attack the bacterial cell as a whole—do not induce the same resistance patterns seen with antibiotics.
At the bedside, our goal is to achieve a microbicidal effect rather than a mere microbiostatic one. By shifting back to evidence-based antisepsis, we protect our patients from unnecessary systemic exposure and the development of resistant strains.
Quick Take To prevent the development of resistance and sensitization, local antibiotics should be avoided for the treatment of locally confined wound infections or colonization.
——————————————————————————–
2. Identifying the “Wound at Risk”: The WAR Score
Not every wound requires an antimicrobial agent. To ensure cost-effectiveness and patient safety, we must first categorize the microbial status. As clinicians, we distinguish between four stages:
- Contamination: Microbes are present on the surface but not proliferating.
- Colonization: Microbes are proliferating, but the host shows no immunological reaction.
- Critical Colonization: Healing is delayed due to toxins/microbial load, even without “classical” infection signs.
- Local Infection: A clear host reaction is present, including erythema (extending 1–2 cm from the margin), heat, swelling, pain, and increased exudate viscosity/odor.
When assessing your patient, use the Wounds-at-Risk (WAR) Score to justify intervention. Assign 1 point for each of the following risk factors:
- Acquired immunosuppressive disease (e.g., Diabetes mellitus).
- Acquired immune defect due to medical therapy (e.g., glucocorticoids, chemotherapy).
- Patient age >80 years.
- Young age of patient (premature infants, babies, infants).
- Wound depth >1.5 cm (in chronic wounds).
- Wound size >10 cm².
- Wounds persisting for >1 year.
- Severe tumor disease or systemic hematological disease.
The Clinical Threshold: Antiseptic treatment is strictly justified when the cumulative WAR Score is 3 points or higher.
——————————————————————————–
3. Silver: The MDRO Specialist (Ag+)
Silver ions (Ag+) remain a powerful tool, but they must be used judiciously.
- Mechanism: Silver ions are the active antimicrobial form. They destroy bacteria by binding to peptide glycans in the cell membrane, disrupting energy generation (ATP) and interfering with cell replication.
- Indications: Indicated for critically colonized wounds or confirmed MDROs.
- The “Dispensable” Agent: We now consider silver-sulfadiazine dispensable. Not only is it cytotoxic, but it forms insoluble complexes with wound proteins that create an adherent “scab.” This effectively hides the wound bed, making it virtually impossible for us to assess burn depth or detect healing progress.
- Evidence Level: Cochrane reviews show silver reduces odor and secretions, but data on accelerated healing remains heterogeneous.
- Practice Tip: Limit use to a maximum of 14 days. If the wound hasn’t improved by then, we must re-evaluate the entire treatment plan.
——————————————————————————–
4. PHMB: The “Detoxified” Antiseptic of Choice
Polyhexamethylene Biguanide (PHMB) is often our first choice for chronic wounds.
- Mechanism: Think of PHMB as a “detoxified” relative of chlorhexidine (CHD). While CHD molecules contain 4-chloroaniline—a potential carcinogen—PHMB lacks this terminal group, making it much better tolerated by human tissue. Furthermore, its efficacy actually increases in the high-pH environment (6.5–8.5) common in chronic wounds.
- Indications: It is the “Antiseptic of Choice” for critically colonized chronic wounds and second-degree burns.
- Contraindications: History of allergy; contraindicated during the first 4 months of pregnancy.
- Evidence Level: Carries Level A support for traumatic and chronic wounds, largely due to its proven analgesic (pain-reducing) effect.
——————————————————————————–
5. Iodophores: Targeted Therapy for Deep Trauma
Iodine has transitioned from a general-purpose agent to a highly specialized one.
- Mechanism: These agents release free iodine for a broad-spectrum microbicidal effect. Cadexomer Iodine (C-I) uses a starch polymer to manage heavy exudate while releasing iodine.
- Indications: PVP-I (aqueous/alcohol) is our 1st choice for acute stab, bite, and gunshot wounds. Its “excellent tissue penetration” makes it the best candidate for heavily destroyed tissue resulting from car crashes or explosions where deep decontamination is mandatory.
- Contraindications: Do not use in patients with thyroid disorders (goiter, Hashimoto’s), Dermatitis herpetiformis Duhring, or before/after radioiodine treatment.
- Age-Specific Safety: PVP-I is contraindicated for infants under 6 months; C-I is contraindicated for children under 12 years.
——————————————————————————–
6. Medical Honey & Hypochlorites
These agents serve unique niches in the cleansing and healing phases.
- Medical Grade Honey: Forms non-cytotoxic H2O2 via glucose oxidase. Research indicates it is more comfortable for the patient than PVP-I, though silver dressings remain more effective than PVP-I at reducing overall wound size.
- Hypochlorites (NaOCl/HOCl): These are the 1st choice for repetitive, intensive cleansing of contaminated traumatic wounds. Because they mimic the body’s natural immune response (phagocytosis), they are the only agents safe for use when there is a risk of CNS exposure or for peritoneal lavage.
——————————————————————————–
7. Comparison Summary: “At-a-Glance” Tool
Note: Before utilizing the table below, note that Octenidine (OCT) is included as it is our primary agent for MDRO decolonization, particularly MRSA.
| Agent | Primary Indication | Key Contraindication | Wound Healing Effect | Clinical “Best For” |
| PHMB | Infected chronic wounds | 1st 4 months of pregnancy | Supportive/Promotes | Chronic ulcers and burns |
| OCT | MDRO decolonization | CNS/Cartilage exposure | No inhibition | MRSA-colonized wounds |
| PVP-I | Acute deep trauma | Thyroid; D. herpetiformis | Partial inhibition | Stab, bite, and gunshot wounds |
| Hypochlorite | Intensive cleansing | None known | Supportive | Decontamination; CNS exposure |
| Silver (Ag+) | MDRO management | Silver-sulfadiazine (avoid) | Can inhibit | Short-term microbial control |
——————————————————————————–
8. Final Clinical Rules for Application
To ensure we are practicing at the highest level of tissue viability standards, adhere to these non-negotiables:
- Diagnosis First: Always determine the underlying etiology (the “why”) before treatment. Antiseptics cannot heal a wound if the underlying ischemia or pressure is not addressed.
- The “Bed” Prep: Debridement and cleansing are mandatory. Antiseptics are largely ineffective when applied over necrotic slough or heavy biofilm.
- The Two-Week Review: Review the therapeutic regimen if there is no improvement after 14 days. Do not continue an unsuccessful treatment indefinitely.
- Pressure Caution: Never apply surfactants (like OCT or PHMB) under pressure into deep cavities, puncture wounds, or abscesses without guaranteed drainage. This can lead to severe edematous swelling and tissue damage.
——————————————————————————–
9. References
Based on the “Consensus on Wound Antisepsis: Update 2018” by Kramer, Dissemond, Kim, et al., published in Skin Pharmacology and Physiology.